Liquid formulation comprising trilostane
AssigneeNorbrook Laboratories Limited
InventorsTim BRANNIGAN, Jonathan BOYD
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to a liquid formulation comprising: (a) trilostane or a pharmaceutically acceptable salt thereof; (b) a viscosity modifier; (c) an organic co-solvent; and (d) water; wherein the organic co-solvent has at least one hydroxy group, and is water-soluble or water-miscible. Also described are uses of the liquid formulation and methods involving the liquid formulation for the treatment or prevention of Cushing's disease or syndrome. A kit of parts including the liquid formulation is also described.
Claims22
A liquid formulation comprising:
- (a) trilostane or a pharmaceutically acceptable salt thereof;
- (b) a viscosity modifier;
- (c) an organic co-solvent;
- and
- (d) water;
- wherein the organic co-solvent has at least one hydroxy group, and is water-soluble or water-miscible.
A method of treating or preventing pituitary-dependent hyperadrenocorticism or adrenal-dependent hyperadrenocorticism in a subject comprising orally administering a liquid formulation, preferably wherein the subject in need thereof is a non-human animal, more preferably a dog or a cat, even more preferably a dog, wherein the liquid formulation comprises:
- (a) trilostane or a pharmaceutically acceptable salt thereof;
- (b) a viscosity modifier;
- (c) an organic co-solvent;
- and
- (d) water;
- wherein the organic co-solvent has at least one hydroxy group, and is water-soluble or water-miscible.
A kit of parts comprising:
- (a) the liquid formulation;
- and
- (b) a syringe, wherein the liquid formulation comprises:
- trilostane or a pharmaceutically acceptable salt thereof;
- a viscosity modifier;
- an organic co-solvent;
- and
- water;
- wherein the organic co-solvent has at least one hydroxy group, and is water-soluble or water-miscible.
Dependencies are inferred from the claim text.